Drug development in pulmonary hypertension: new approaches to gather knowledge

1 June 2022

  • days
  • Hours
  • Minutes

Chair and moderators

Harm Jan Bogaard, Amsterdam UMC, the Netherlands

Kelly Morland, United Therapeutics, USA

Agenda

  • The use of master protocols and a platform design: lessons from COVID-19 therapeutic trials
  • A platform trial and master protocol for PAH clinical trials: is it feasible, and if so, which drugs do we want to study?
  • The use of RWD/RWE in bringing drugs to PH patients
  • RWD/RWE in PH: what are the questions and can we get the answers?

A deeper look

The use of master protocols and a platform design: lessons from COVID-19 therapeutic trials

14:00-14:15 BST

Presenter: // Lisa Lavange, University of North Carolina, USA

 

A platform trial and master protocol for PAH clinical trials: is it feasible, and if so, which drugs do we want to study?

14:15-14:30 BST

Panel discussion: // Ardeschir Ghofrani, Roham Zamanian, CQ Deng & Mardi Gomberg-Maitland

 

The use of RWD/RWE in bringing drugs to PH patients

14:30-14:45 BST

Presenter: // Steve Mathai, Johns Hopkins University, USA

 

RWD/RWE in PH: what are the questions and can we get the answers?

14:45-15:00 BST

Panel discussion: //

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI
standard-example-image.jpg